Rigel Pharmaceuticals (NASDAQ: RIGL) — Company Overview, News & Financial Data
Rigel Pharmaceuticals specializes in small molecule drugs for rare diseases, focusing on immunology and oncology.

Rigel Pharmaceuticals
Rigel Pharmaceuticals (NASDAQ:RIGL) specializes in discovering, developing, and marketing novel small molecule drugs for the treatment of rare diseases. The company focuses on immunology, oncology, and immune-oncology programs. Their pipeline is rich with projects aiming to target various diseases with unmet medical needs, working on both internally discovered and externally sourced compounds. Objectives include advancing their research to bring innovative therapies to patients while pursuing strategic partnerships and collaborations to expand their reach and capabilities. With a commitment to scientific excellence, Rigel Pharmaceuticals aims to improve the lives of patients suffering from rare and serious diseases through cutting-edge research and drug development.
Snapshot
Operations
Products and/or services of Rigel Pharmaceuticals
- Fostamatinib, used in treating chronic immune thrombocytopenia, a disorder causing excessive bruising and bleeding due to low platelet counts.
- R835, an experimental oral IRAK1/4 inhibitor for autoimmune and inflammatory diseases.
- Fostamatinib's investigation in COVID-19 patients, exploring its efficacy in combating virus-related complications.
- Collaboration with Eli Lilly for the discovery and development of immunological therapies.
Rigel Pharmaceuticals executive team
- Raul R. RodriguezPresident, CEO & Director
- Dean L. SchornoExecutive VP & CFO
- Raymond J. FureyExecutive VP, Chief Compliance Officer, General Counsel & Corporate Secretary
- David A. SantosExecutive VP & Chief Commercial Officer
- Alison L. HannahExecutive VP & Chief Medical Officer
- Julie PatelSenior VP of Human Resources
- Joseph LasagaExecutive VP & Chief Business Officer
- Tarek SallamVice President of Marketing
Recent announcements
What Rigel Pharmaceuticals (RIGL) has told the market, newest first.
Key financials
Reported results for Rigel Pharmaceuticals, in USD.
- Market cap
- 800.8M
- Revenue (TTM)
- 288.2M
- P/E ratio
- 2.6
- EPS (diluted, TTM)
- 16.1
- Dividend yield
- —
- Profit margin
- 106.6%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 294.3M | 125.5M | 367M | |
| 179.3M | 24.2M | 17.5M | |
| 116.9M | -20.5M | -25.1M | |
| 120.2M | -55.6M | -58.6M |